Neuland Labs Q3FY26 Results: Revenue at ₹439.7 Cr, Profit ₹40.5 Cr
Neuland Laboratories Limited reported unaudited results for Q3FY26. Consolidated revenue was ₹447.71 crore and profit after tax was ₹40.57 crore. For the nine-month period, revenue stood at ₹1,264.44 crore with a profit after tax of ₹151.33 crore. The results were approved by the Board on February 9, 2026.
The decrease in profits compared to the prior year, while significant, does not suggest an immediate crisis but warrants attention. Investors will likely monitor future performance closely.
The reported profit after tax for the quarter and nine months ended December 31, 2025, shows a significant decrease compared to the same periods in the previous year, indicating a negative financial performance trend.
Neuland Laboratories Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results on February 9, 2026.
For the quarter ended December 31, 2025, the company reported consolidated total income of ₹44,776.17 lakhs (₹447.71 crore) and a profit after tax of ₹4,057.19 lakhs (₹40.57 crore). This compares to a total income of ₹40,193.74 lakhs (₹401.94 crore) and a profit after tax of ₹10,158.68 lakhs (₹101.59 crore) for the corresponding quarter in the previous year.
For the nine months ended December 31, 2025, the consolidated total income stood at ₹1,26,444.31 lakhs (₹1,264.44 crore), with a profit after tax of ₹15,132.58 lakhs (₹151.33 crore). In the same period last year, the total income was ₹1,16,152.23 lakhs (₹1,161.52 crore) and profit after tax was ₹23,230.22 lakhs (₹232.30 crore).
The company's operations are primarily in the manufacture of active pharmaceutical ingredients and allied services, with geographical segments including India, Europe, USA & North America, and Rest of the World. The financial results were reviewed by the Audit Committee and approved by the Board of Directors. The detailed financial results and auditor's limited review reports are available on the company's website.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.